<DOC>
	<DOCNO>NCT00310518</DOCNO>
	<brief_summary>The purpose study ass overall response rate ( ORR ) persistent , recurrent metastatic leiomyosarcoma patient treat ARQ 501 .</brief_summary>
	<brief_title>Safety Efficacy Study ARQ 501 Adult Patients With Leiomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>Able provide sign date informed consent prior studyspecific screening procedure . Histologically cytologically confirm leiomyosarcoma persistent , recurrent metastatic . Measurable disease define RECIST . Karnofsky performance status &gt; = 70 % Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last infusion ARQ 501 . Hemoglobin ( Hgb ) &gt; = 10 g/dL . Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L ( &gt; = 1,500/mm3 ) . Platelet count &gt; = 100 x 10^9/L ( &gt; = 100,000/mm3 ) . Total bilirubin less equal 1.5 x upper limit normal ( ULN ) less equal 3.0 x ULN metastatic liver disease . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less equal 2.5 x ULN le equal 5.0 ULN metastatic liver disease . Creatinine le equal 1.5 x ULN . Received three prior anticancer chemotherapy regimen . Have active , uncontrolled systemic infection consider opportunistic , life threaten clinically significant time treatment . Have receive anticancer chemotherapy , immunotherapy , radiotherapy , surgery investigational agent within four week first infusion . Have symptomatic untreated central nervous system ( CNS ) involvement . Are pregnant breastfeeding . Previous exposure ARQ 501 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>